Summary The matrix metalloproteinases are a family of enzymes that degrade the extracellular matrix and are considered to be important in tumour invasion and metastasis. The effect of epidermal growth factor (EGF) on matrix metalloproteinase-1 (MMP1) production in two human bladder tumour cell lines, RT112 and RT4, has been investigated. In the RT112 cell line, an increase in MMP1 mRNA levels was found after a 6-h incubation with EGF, and this further increased to 20-fold that of control levels at 24-and 48-h treatment with 50 ng ml-1 of EGF. MMP2 mRNA levels remained constant over this time period, whereas in the RT4 cells no MMP2 transcripts were detectable, but MMP1 transcripts again increased with 24-and 48-h treatment with 50 ng ml-' of EGF. MMP1 protein concentration in the conditioned medium from both cell lines increased with 24-and 48-h treatment of the cells and the total MMP1 was higher in the medium than the cells, demonstrating that the bladder tumour cell lines synthesize and secrete MMP1 protein after continuous stimulation with EGF. MMP1 protein was detected in urine from patients with bladder tumours, with a significant increase in concentration with increased stage and grade of tumour. MMP1 urine concentrations may therefore be a useful prognostic indicator for bladder tumour progression.
The matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that contain a zinc atom at their active site. They are found in both normal and pathological tissue in which matrix remodelling is involved, including embryonic development, wound healing, arthritis and angiogenesis, as well as tumour invasion and metastasis (Matrisian, 1990; Liotta et al, 1991) . The enzymes, which are cytoplasmic or membrane type , are secreted in a latent (pro) form and require activation by removal of approximately 80 amino acids from the propeptide, and other metalloproteinases and proteases are involved in this activation (Powell and Matrisian, 1996; Stetler-Stevenson et al, 1996) . Additional regulation of the enzymes is by endogenous tissue inhibitors of metalloproteinases (TIMPS), of which four have now been identified (Greene et al, 1996) . These proteins form a stable non-covalent complex with the enzymes, inhibiting their activity. Various members of the MMP family and their inhibitors have been studied to elucidate their role in cancer, in which deregulation of their expression and function has been implicated in the invasion of normal tissues by tumours and their subsequent metastatic spread. Invasive tumour progression is particularly evident in bladder cancer, in which it is a central feature of the prognostic staging system. Bladder cancer is the fifth most common cancer in men, and transitional cell carcinoma (TCC) of the bladder can be broadly divided into superficial (Ta and T1) or muscle invasive (T2, T3 and T4) forms. Approximately 50-70% of superficial tumours recur, but 10-20% will become invasive. At present, there is no reliable method to predict which superficial tumours will show invasive progression or metastasize. In bladder cancer (Davies et al, 1993 ) the gelatinases (MMP2 and MMP9) were found to be higher in invasive than in superficial tumours. MMP2 has also been shown to be elevated in the urine of patients with TCC of the bladder (Margulies et al, 1992) . A study by Naruo et al (1993) reported that mRNA levels of MMP2, TIMP2 and TIMPl increased in cases with invasion and metastasis of bladder cancers, and the ratio of MMP2/TIMP2 increased as invasion and metastasis progressed. In this study, there was also a correlation between MMP2 and c-fos proto-oncogene expression. A positive correlation between serum TIMPI levels and invasion and metastasis in patients with bladder cancer has also been reported (Naruo et al, 1994) . More recently, it has been reported that the mean serum MMP2/TIMP2 ratio was higher in patients with recurrence of urothelial cancer than in those without recurrence and that the disease-free survival of patients with a high MMP2/TIMP2 ratio was extremely poor (Gohji et al, 1996a) . The elevation of serum levels of either MMP2 or MMP3, or both, were also shown to be possible predictors of recurrence in patients with advanced urothelial carcinoma after resection (Gohji et al, 1996b) . In contrast Grignon et al (1996) suggests that there is a strong correlation between high levels of TIMP2 immunostaining and poor outcome in patients with invasive bladder cancer.
Growth factors and their receptors are important in tumour development and progression and several studies have shown that the presence of epidermal growth factor receptor (EGFR) in bladder cancer is associated with high tumour stage and grade and is a strong independent predictor of tumour progression and poor long-term survival (Lipponen and Eskelinen, 1994; Mellon et al, 1995) . Levels of epidermal growth factor (EGF) are known to be high in urine with a mean value of 80 ng ml-' (Fisher and Lakshmanan, 1990 ), but are lower in patients with bladder tumours and rise again after surgery (Fuse et al, 1992) . Signal transduction pathways stimulated by EGF induce the activator protein-i (AP-1) transcriptional regulatory complex (Edwards et al, 1987) , which is a known positive transcriptional regulator of MMP1 expression and stromelysin (MMP3) (McDonnell et al, 1990) in fibroblasts. We have previously reported the induction of MMP1 (interstitial collagenase) expression by EGFR stimulation in the human breast cancer cell line MDA-MB-23 1 (Nutt and Lunec, 1996 
RNA extraction and Northern blot analysis
Total RNA was extracted from the frozen cell pellets using the phenol-guanidinium isothiocyanate method using a commercial reagent RNAzol (Biogenesis, Poole, UK), followed by chloroform extraction and isopropanol precipitation. After washing with 70% ethanol, the RNA pellet was dissolved in water, the concentration determined by absorbance at 260 nm and the samples stored at -70°C.
Northern blot analysis was performed using the glyoxal method as previously described (Nutt et al, 1991) . Briefly, 20 jig samples of RNA were treated by glyoxylation before electrophoresis on 1.2% agarose gel in 10 mm phosphate buffer. The gel was stained with ethidium bromide to verify equal loading of samples before capillary transfer of the RNA overnight onto Hybond-N nylon membrane (Amersham International, Little Chalfont, UK). After transfer and air drying, RNA was fixed to the membrane by ultraviolet irradiation cross-linking for 3.5 min using a mid-range transilluminator (UltraViolet Products, UK). Radioactive probes were prepared by the random primer extension method (Feinberg and Vogelstein, 1983) . Probes for c-fos and MMP1 were prepared from cDNA clone inserts, obtained from A Sharrocks (Newcastle upon Tyne) and P Angel respectively. Probes for MMP2 and 18S rRNA were prepared by polymerase chain reaction (PCR) (Clifford et al, 1994 ) from available cDNA stocks using primers from published sequences. The primer pairs used were MMP2: SN 218 5'-CTTGACCAGAATAC-CATCG-3', ASN 373 5'-ACGAGCAAAGGCATCATCC-3'; 18S: SN 864 5'-ATGCTCTTAGCTGAGGTGTCC-3', ASN 1154 5'-AACTACGACGGTATCTGATCG-3'.
PCR products were electrophoresed in a 1.2% low-meltingpoint agarose gel and the product detected and yield estimated by ethidium bromide staining. The product band was cut from the gel, melted by heating to 65°C and approximately 20-jg aliquots were used directly in the random primer extension radioactive labelling reaction, as previously described (Feinberg and Vogelstein, 1983 SDS for 15 min was also used for the c-fos and MMP2-probed filters. To detect the bound radioactivity, the filters were exposed to a Phosphorlmager screen (Molecular Dynamics, UK). The filters were stripped in boiling water for 5 min before reprobing, the 18S rRNA probe being a control for equal sample loading.
Measurement of MMP1 concentration in conditioned medium, cells and urine For each sample of cells, 40 ml of conditioned medium was collected. The conditioned medium from cells was concentrated eightfold at 4°C using Centricon-10 concentrators (Amicon, Gloucestershire, UK). The concentrate was used for the measurement of total MMP1 protein using the Biotrak MMP1 ELISA system (Amersham International, UK) and the results corrected for the concentration factor. All measurements were performed in duplicate. The assay is based on a two-site ELISA sandwich format and MMP 1 concentration is determined by optical density readings at 450 nm and interpolation from a standard curve. Pelleted frozen cells were lysed by sonication in 1 ml of 50 mm Tris-HCl, pH 7.4. The sample was centrifuged for 15 min at 10 000 g at 4°C and the supematant used for the measurement of total MMP1 protein.
Urine samples and patient details Urine samples were collected from patients immediately before check cystoscopy or cystectomy. Samples were centrifuged and the supernatant frozen at -20°C. Samples were subsequently concentrated up to tenfold using the Centricon-10 concentrators and the concentrate used in the MMPI ELISA assay in duplicate as above. MMP1 protein concentrations were adjusted for the concentration factor for each sample. Urine samples were analysed blind and, retrospectively, the samples were from ten patients with stage T2-T4 tumours, five stage T1 and 17 stage Ta tumours, and 17 patients who had no detectable tumour at cystoscopy. The stage of tumour was according to the TNM system and the grade according to the WHO classification.
RESULTS
Effect of EGF on mRNA in RT112 and RT4 cells RT1 12 cells were initially incubated with two concentrations of EGF for 30 min-6 h. Figure 1 A shows the induction of c-fos transcripts as an early response to stimulation of the cells for 0.5 and 1 h with both doses of EGF. The levels of c-fos mRNA returned to control values by 2 h. This induction offos mRNA shows that the bladder tumour cells responded to treatment with EGF. The result of probing for MMP2 transcripts is also shown in Figure 1 , but these remained constant with both doses of EGF for up to 4 h of treatment. Reprobing for 18s rRNA demonstrated equal loading and transfer of RNA in these experiments. Figure 1B shows the detected transcripts levels for MMPI and MMP2 for up to 6 h of incubation. Again, MMP2 transcripts remained constant, but by 6 h the levels of MMP1 transcripts were observed to increase, particularly with the higher dose (50 ng ml-') of EGF. British Journal of Cancer (1998) 78(2), [215] [216] [217] [218] [219] [220] 0 Cancer Research Campaign 1998 EGF at both time points (Figure 2A ). Figure 2B . An eightfold increase in transcripts was seen at both 24 and 48 h with 50 ng ml EGF treatment, and a twofold increase with 10 ng ml EGF at 24 h. Again, no increase in MMP1 transcripts was found in controls after 48-h incubation. No MMP2 transcripts were detectable in RNA extracts from the RT4 cells.
MMP1 protein concentration in cells and conditioned medium
The concentration of total MMP1 protein in conditioned medium and cell extracts is shown in Figure 3 . In RT112 cells, MMP1 was detected in medium at 24 h and increased at 48 h, whereas levels in the cells remained constant. In RT4 cells, concentrations of MMP1 were seen to increase in both the cells and the medium at 24 and 48 h. However, the total amount of MMP1 in medium far exceeded that in the cells, as 40 ml of medium was collected from each sample of cells. MMP1 protein was below detectable levels in medium from cells treated for less than 24 h.
MMP1 protein in urine samples
After concentration of the urine samples, total MMP1 was detected in a proportion of the samples, as shown in Figure 4A , where the MMPI concentration is shown in relation to tumour stage. The normal controls and most patients who were clear of tumours at cystoscopy were found to have very low or undetectable levels of MMP1. For those patients with tumours, elevated levels of MMP1 protein were found in the urine of cases with invasive (T2-T4) tumours compared with samples from patients with superficial disease only (Ta, TI or cis). Using the Mann-Whitney T-test, urine from patients with invasive tumours (T2-T4, n = 10) had statistically significantly higher MMP1 concentrations (median value of 1.23 ng ml-') than the patients with superficial (Ta-T1, n = 22) tumours, median value of 0.09 ng ml-(P = 0.029) and, in addition, significantly higher concentrations compared with samples from patients (n = 17) who were diagnosed as being clear of tumours, median value of 0.0 ng ml-} (P = 0.003). The MMP1 concentration in urine in relation to tumour grade is shown in Figure 4B . The median values increase with the tumour grade -0 ng mll for G1, 0.25 ng ml-l for G2 and 0.68 ng ml-' for G3 tumours -with a significant difference between the MMP1 concentration in the urine of patients with G1 and G3 bladder tumours (P < 0.0001).
DISCUSSION
These results demonstrate that the EGFR-positive bladder tumour cell line RTl 12 responds rapidly to stimulation by EGF, as evidenced by an increase in the transcript levels of the early response gene c-fos within 30 min. This is consistent with induction by EGF of the API transcription factor of which the c-fos protein product is a part. Later increases in transcripts for MMP1 are also seen as a result of EGF stimulation in both RT 1 12 and RT4 cell lines. The lack of change in MMP2 transcript levels after EGF stimulation of the RT112 cells is further evidence that different (Benbow and Brinckerhoff, 1997) . It is also interesting that no MMP2 transcript was detectable in the RT4 cells, demonstrating marked differences in the pattern of expression of this gene family in different cell lines from the bladder.
The concentration of MMP1 found in the conditioned medium of both bladder tumour cell lines not only demonstrates that, after EGF stimulation, the cells increase the MMPI mRNA levels but also that this is translated into increased protein that is secreted by the epithelial tumour cell lines. It is therefore possible that, in bladder tumours, it is the epithelial cells rather than the stromal cells that produce and secrete MMP1 into the urine. It has recently been reported (Nakopoulou et al, 1997) that MMPI was detected by immunohistochemistry in the cytoplasm of neoplastic cells in 20% of bladder tumours investigated. The increase in MMP1 in the medium with time also demonstrates a continual secretion of the protein into the medium in the continued presence of EGF. In the RT4 cell line, the increase in mRNA with the two doses of EGF is not followed exactly by increases in the protein concentrations. This suggests that control of expression may not be just at the transcriptional level but that translational or post-translational mechanisms may come into play if protein synthesis is maximal and the message is still being increased. The higher dose of EGF used (50 ng ml') is a similar concentration to that in urine (Fisher and Lakshmanan, 1990) MMP1 in bladder tumour cells and urine 219 increase MMP expression and secretion, and thus contribute to tumour progression and metastasis. This is similar to the response of human oral squamous cell carcinoma (SCC) cell lines (Shibata et al, 1996) in which MMP9 was increased with doses of EGF greater than 10 ng ml-', which is ten-to 100-fold less than the EGF concentration in saliva. In the context of bladder cancer, these observations may also help provide a mechanism to explain the observation that EGFR expression is more frequently associated with high tumour stage and grade, and where it is found expressed in superfical tumours is a strong predictor of invasive progression when these tumours recur (Mellon et al, 1995) . Our initial study on MMP1 concentrations in the urine of patients with bladder tumours indicates that higher concentrations of MMPI are detected in patients with higher stage and higher grade tumours. The measurement of MMP I in urine may be a useful non-invasive indication of possible tumour progression, particularly in the EGFR-positive bladder tumours in which the prognosis is poor.
From a study of MMP1 in colorectal cancer (Murray et al, 1996 ) using immunohistochemistry, it was reported that the presence of MMP1 was associated with poor prognosis and furthermore showed prognostic significance independent of tumour stage. In 16% (n = 10) of the tumours showing immunoreactivity, more than 90% of tumour cells were positive. MMPI has also been found to be localized in the carcinoma cells of gastric tumours (Nomura et al, 1996) , whereas in thyroid cancer the MMP1 gene was reported to be expressed in the fibrous capsules of papillary carcinomas and not in the cancer cells (Kameyama, 1996) . MMPI has also been detected by immunohistochemistry in the tumour cells of some brain neoplasms (Nakagawa et al, 1994) , using in situ hybridization in head and neck carcinoma (Muller et al, 1993) and also in pulmonary carcinoma (Urbanski et al, 1992) . Thus, MMP1 appears to be commonly expressed in human tumours, and the present study shows this to be extended to the detection of elevated MMPI protein levels in the urine of bladder cancer patients, and this is associated with invasive high-grade tumours. This is consistent with the observed induction of MMP I expression in cultured bladder tumour cells stimulated with EGF and the known association of EGFR expression with high tumour stage and grade in bladder cancer.
These studies further demonstrate the frequent expression of matrix metalloproteinases in cancer and particularly highlights the regulation of MMP1, which is now easily detectable in low concentrations in tumour cells and body fluids with the use of specific antibodies. The detection of MMP 1 in the urine of patients with invasive bladder tumours requires further investigation and suggests that early detection of significant levels of the enzyme in patients with superficial tumours should be tested as a potential predictor of invasive progression. The causal role of MMP1 expression in tumour invasion and its regulation via EGFRdependent signalling pathways should be investigated further.
